Analysis Sheds Light on Bevacizumab “Reversals” in Glioblastoma
Improvements to PFS and “clinically meaningful reductions in daily corticosteroid use” were said to be linked to the addition of bevacizumab in glioblastoma.
All articles by Agata Boxe
How to Treat Melanoma After Checkpoint Inhibitors Fail
The combination of ipilimumab and nivolumab resulted in a higher rate of objective remissions compared with ipilimumab alone.
Adjuvant Ipilimumab Determined to Increase Overall Survival in High-Risk Melanoma
Adjuvant ipilimumab may improve overall survival in patients with resected high-risk melanoma.
Neoadjuvant Therapy in Melanoma Tied to High Pathological Response Rates
Researchers concluded that the ability to achieve pCR correlated to improved recurrence-free survival in melanoma.
No Link Found Between HRD and Pathologic Response in Triple-Negative Breast Cancer
One of the study’s primary objectives was to detect an association between homologous repair deficiency and pathologic response.
Paclitaxel Plus Olaparib Linked to Better Outcomes in Some Breast Cancer Patients
Paclitaxel plus olaparib may result in a higher pathological complete response (pCR) rate than paclitaxel plus carboplatin — followed by epirubicin and cyclophosphamide — but only in some groups of patients.
Extended Letrozole Provides Benefit After Adjuvant Tamoxifen
Extended adjuvant treatment with additional 5 years of letrozole was associated with a 19% reduction in invasive disease-free survival events, said authors.
Heparin Derivative CX-01 May Boost Standard AML Induction
The new findings suggest that CX-01 may strengthen the efficacy of standard AML induction.
Novel Metric Sheds Light on When Adverse Events May Occur
Longitudinal toxicity analysis can be used to guide adverse event interventions.
Sequential Exposure to FOLFOXIRI Plus Bevacizumab Shows Benefit in Unresectable mCRC
The reintroduction of FOLFOXIRI/bev in the progressive setting may provide a further benefit in mCRC.
Next post in ASCO 2019
